UNSPSC 51152039: Nelezaprine

This classification denotes a muscle relaxant with the molecular formula C18H21ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OC19J8O751, chemically known as (3E)-3-(9-chloro-5,6-dihydropyrrolo[1,2-c][3]benzazepin-11-ylidene)-N,N-dimethylpropan-1-amine but generally known as nelezaprine, which bears US NIH Compound Identifier 6436130. European Medicines Agency schedules nelezaprine its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09185MIG.

Most nations schedule nelezaprine under HS 29339930 and SITC 51577. As of Q4 2014, NELEZAPRINE remains the US FDA Preferred Term for this commodity. Nelezaprine bears US NLM identifiers UMLS ID C2983927 and NCI Concept Code C90893. SMILES: CN(C)CCC=C1C2=CC=CN2CCC3=C1C=C(C=C3)Cl.

UNSPSC 51152039 Nelezaprine is a Commodity code that, based on recent state and local activity, encompasses pharmaceutical products and drug-related medical supplies procured to support public health and community health initiatives. State and local governments buying under this code are acquiring naloxone (opioid reversal medication) and drug deactivation systems for emergency response and harm-reduction programs. Issuing bodies include county health departments and state health and human services agencies. The code also captures broader pharmacy benefit program initiatives where state agencies seek to establish direct-to-manufacturer prescription fulfillment arrangements outside traditional pharmacy benefit manager and wholesaler channels.

Seminole County, Florida posted an IFB in late June 2026 (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the contract carries a two-year initial term with a one-year renewal option and is potentially FEMA-funded. The Texas Health and Human Services Commission issued an RFI in April 2026 (HHS0017013, due April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct state contracting with pharmaceutical manufacturers to improve fulfillment efficiency and cost management. Recent activity spans Florida and Texas, with procurement mechanisms ranging from traditional competitive bidding (IFB) to preliminary market intelligence (RFI) to inform future formal solicitations.